Search results
Results from the WOW.Com Content Network
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
Non-stimulant medications are recommended for the 15-30% of children with ADHD who don't respond to stimulants, per the Child Mind Institute. They may also be a good option for children who ...
An estimated 6 million children ages 3 to 17 have been diagnosed with ADHD, and 62% of those kids take medication for it, according to the Centers for Disease Control and Prevention (CDC). “For ...
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.
Methylphenidate, sold under the brand names Ritalin (/ ˈ r ɪ t ə l ɪ n / RIT-ə-lin) and Concerta (/ k ə n ˈ s ɜːr t ə / kən-SUR-tə) [citation needed] among others, is a central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy.
Atomoxetine, sold under the brand name Strattera among others, is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) [12] and, to a lesser extent, cognitive disengagement syndrome (CDS). [13] [14] [15] It may be used alone or along with stimulant medication.